$2.72
+0.04 (+1.49%)
Open$2.71
Previous Close$2.68
Day High$2.73
Day Low$2.70
52W High$5.46
52W Low$2.32
Volume—
Avg Volume166.0K
Market Cap92.12M
P/E Ratio—
EPS$-0.31
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Price Target
+458.1% upside
Current
$2.72
$2.72
Target
$15.18
$15.18
$12.50
$15.18 avg
$18.81
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 12.06M | 11.02M | 11.79M |
| Net Income | 2.28M | 2.12M | 2.45M |
| Profit Margin | 18.9% | 19.3% | 20.8% |
| EBITDA | 3.37M | 3.22M | 3.75M |
| Free Cash Flow | 1.70M | 2.02M | 1.47M |
| Rev Growth | +16.3% | -0.5% | +13.7% |
| Debt/Equity | 1.56 | 1.35 | 1.56 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $295.03 | +0.20% | 50.3 | 520.47B |
| AMGN | Amgen Inc | $465.67 | -0.30% | 26.9 | 252.64B |
| GILD | Gilead Sciences Inc | $168.08 | +0.08% | — | 208.95B |
| VRTX | Vertex Pharmaceuticals Inc | $538.60 | -0.74% | 33.9 | 134.82B |
| REGN | Regeneron Pharmaceuticals | $955.47 | +0.45% | 20.4 | 98.38B |
| ALNY | Alnylam Pharmaceuticals Inc | $165.04 | +5.36% | 7.7 | 20.98B |